Emerald Health

"Cannabinoids have the potential to revolutionize treatments of the eye." - CEO of Emerald Bioscience Inc., Dr. Brian Murphy. It was an honor for Dr. Murphy to participate on the "Clinical Research in Cannabinoids" panel today alongside fellow industry thought leaders at the Cowen 2nd Annual Boston Cannabis Conference. #CowenCannabis

Emerald Health Therapeutics announced today that it has received organic certification for cannabis production at its Metro Vancouver operation in British Columbia, which encompasses 156,000 square feet in two greenhouses as well as 12 acres of licensed outdoor cultivation area. Full press release: http://bit.ly/2O3kUgI

Emerald Health Therapeutics is proud to announce that it has signed an agreement to become a new supplier to STENOCARE A/S of medical cannabis for Denmark and STENOCARE’s international markets. Emerald's medical cannabis products will be distributed into STENOCARE’s established Danish pharmacy and hospital channels. Full press release: http://bit.ly/33rb9iP

The role of the Endocannabinoid System as the body’s innate balancing (adaptogenic) mechanism is key to the regulation of everything from appetite, energy metabolism, fertility and immunity to sleep, mood, pain perception and memory. There is virtually no function in the human body that does not benefit from a healthy ECS. Learn more: http://bit.ly/2ndTqeB

#EmeraldCoSpotlight Emerald Health Pharmaceuticals is focused on the development of a new class of drugs with targeted mechanisms of action aimed at bringing innovative therapies to patients to treat diseases with significant unmet medical needs, including multiple sclerosis, systemic sclerosis (a form of scleroderma), Parkinson’s disease and Huntington’s disease. Learn more about EHP: http://bit.ly/35lESes

Emerald Health Therapeutics has completed planting at its indoor Québec facility, Verdélite, and expects to complete planting in the next days in the first of its two greenhouses in Metro Vancouver, allowing for transition into the commercial phase of these operations and a significant increase in quality cannabis production with approximately 7,500kg of product output targeted for these facilities in 2020. http://bit.ly/2ON1xc7

#EmeraldCoSpotlight Emerald Bioscience Inc. is a #biopharmaceutical company focused on the development of bioengineered #cannabinoid-based #therapeutics for the potential treatment of diseases with significant unmet medical needs, such as #glaucoma, in global markets. Learn more about the company’s mission: http://bit.ly/2lND1gG

Emerald Health Pharmaceuticals is now on Facebook! The EHP team is focused on developing unique medicines based on #cannabinoidscience and technology for diseases with significant unmet medical needs, including multiple sclerosis, systemic sclerosis (a form of scleroderma), Parkinson's disease and Huntington's disease. We invite you to join them to get to know the team and stay up to date on their latest corporate news and company developments.

Emerald Health Bioceuticals' Endo Immune natural health supplement has received Taste for Life's 2019 Immunity Essentials Award for Best Herbal Blend. The Taste for Life Immunity Awards honor the top science-backed products in the #healthandwellness industry for their effects in strengthening immunity. Congratulations team! Learn more about the #endocannabinoidsystem: http://bit.ly/376liUB

Emerald Health Therapeutics' Puresunfarms JV Records Q3 Net Sales of $24.0 Million, 69% Gross Margin, 56% EBITDA Margin, Fourth Consecutive Quarter of Positive EBITDA, and $0.63/gram All-in Production Cost. Full press release: http://bit.ly/2QnpDMU